+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: Ionis Pharmaceuticals

  • ID: 5357328
  • Company Profile
  • January 2021
  • 44 pages
  • Datamonitor Healthcare
The publisher explores Ionis Pharmaceuticals’ prescription pharmaceutical performance and outlook over 2019-29.

Snapshot
  • Overview - Ionis’s prescription pharmaceutical business will see strong growth over the forecast period.
  • Key themes - [1] Spinraza royalties will comprise the majority of Ionis’s revenues for the foreseeable future [2] Pharmaceutical business growth driven by launches of Tegsedi and Waylivra.
Model updates (4 November 2020)
  • Tegsedi forecast adjusted lower
Model updates (5 August 2020)
  • Tegsedi forecast adjusted lower due to sales trends
  • Waylivra forecast adjusted lower due to sales trends
  • Other revenue adjusted lower due to lower upfront licensing fees.
Model updates (6 May 2020)
  • No changes to forecast.
Model updates (26 February 2020)
  • Waylivra forecast adjusted lower due to slower-than-anticipated launch.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Recent Earnings Review
  • Earnings Overview
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll